NCT07546812
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Study sites: 15 to 16
- Notable Eligibility criteria expanded, about 19 words
- Trial sites expanded: 12 → 15 locations
- Minor Trial sites expanded: 4 → 12 locations
- Start date changed from estimate of Jul 2026 to Aug 7, 2026
- Notable Start date: May 2026 to Jul 2026
- Trial sites expanded: 1 → 4 locations
- Notable Recruitment opened
- Eligibility criteria expanded, about 20 words
- Study sites: 0 to 1
- Start date: Apr 2026 to May 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Participants will receive DEN Dose A as an IV infusion in combination with NIVO as an IV infusion.
Participants will receive DEN Dose B as an IV infusion in combination with NIVO as an IV infusion.
Participants will receive DEN Dose B as an IV infusion.
Participants will receive DEN in combination with ramucirumab (RAM) and paclitaxel (PAC). If dose for DEN is deemed safe during the SRI Cohort, the study will move forward into the Expansion Period.
If DEN dose is deemed safe in Arm D: SRI Cohort, participants will receive DEN at recommended dose as an IV infusion in combination with RAM and PAC.
Drugs: Denikitug, Nivolumab, Ramucirumab, Paclitaxel
Sites
16 sites in 5 countries
Australia 5, Spain 4, United States 4, France 2, South Korea 1